Apoptosis plays a role in cardiomyocyte death in several cardiovascular disorders. Here, we show that primary postnatal cardiomyocytes did not die upon activation of the intrinsic (cytochrome c-dependent) apoptotic pathway. Release of cytochrome c from mitochondria to the cytosol occurred, but did not activate the effector phase of apoptosis. Myocardial cells did not express apoptotic protease-activating factor-1 (Apaf-1), the allosteric activator of caspase-9 acting downstream of cytochrome c release. Forced expression of Apaf-1 restored the competence to complete the cytochrome c-induced apoptotic program and this effect was prevented by overexpression of Bcl-X L . However, cardiomyocytes were able to enter the apoptotic program when it was initiated by activation of death receptors, as observed during serum deprivation and metabolic inhibition. Our results indicate that regulation of Apaf-1 expression may be a new regulatory mechanism developed in postmitotic cells in order to prevent irreversible commitment to die after release of cytochrome c.
Introduction
Cardiomyocyte apoptosis occurs during the course of certain cardiovascular diseases such as cardiomyopathy, hypertension and during rejection. [1] [2] [3] [4] Postnatal cardiomyocytes are terminally differentiated cells that are not able to divide at a rate allowing for the replacement of dead cells. 5 Ongoing cellular loss in these conditions could be a determining factor in the progression to heart failure, 6 although the relative contribution of the apoptotic pathways has not been fully elucidated. Furthermore, it has been reported that myocardial apoptosis could be incomplete in the failing human heart, 7 and that cleavage of executioner caspases is low in cardiomyocytes compared with surrounding endothelium in the rat heart upon ischemia/reperfusion-induced injury. 8 These data suggest the existence of unknown antiapoptotic mechanisms in cardiomyocytes.
In mammals, caspase-dependent programmed cell death occurs through at least two main pathways. In the extrinsic pathway, activation of death receptors located on the cytosolic membrane triggers an intracellular signaling cascade involving the activation of caspase-8, which in turn cleaves and activates executioner caspases, 9 inducing disruption of cell homeostasis, 10 internucleosomal DNA fragmentation 11 and cell death. On the other hand, in the intrinsic (mitochondrial) pathway, mitochondrial proteins such as cytochrome c and SMAC/DIABLO are released into the cytoplasm under several stress situations. In the cytosol, cytochrome c and ATP catalyze the oligomerization of apoptotic protease-activating factor-1 (Apaf-1), which recruits and activates caspase-9 inducing the processing and activation of executioner caspases. 12, 13 Our attempts to induce programmed cell death in rat neonatal cardiomyocytes by treatment with staurosporine (STS), a wide range apoptosis-inducing agent, which triggers the release of cytochrome c into the cytosol by a mechanism involving Bak and Bax, 14, 15 revealed that the execution phase of apoptosis did not occur despite cytochrome c translocation. We investigated this phenomenon and characterized the downstream regulation of apoptosis in this setting. Our findings revealed the absence of Apaf-1 expression, which prevented cytochrome c release from activating executioner caspases. In fact, induction of Apaf-1 expression leads to nuclear fragmentation of cardiomyocytes after STS treatment and this effect was blocked by coexpression of antiapoptotic Bcl-2 family member Bcl-X L , which is reported to prevent cytochrome c release. In contrast, serum deprivation and glucose metabolism inhibition, which has been recently described to induce apoptosis dependent on death receptor activation in cardiomyocytes, 16 triggered the complete apoptotic program.
0.01 to 1.0 mmol/l after 24 h of treatment ( Figure 1a) . Myocardial resistance to STS-induced toxicity did not diminish with an increasing time of exposure (Figure 1b) , whereas cell death reached 100% in endothelium after 48 h (Figure 1b) . Cytoplasm condensation, an early feature of apoptosis, was induced by STS both in rat cardiomyocytes and in endothelial cells (Figure 1c) , although the degree of cell shrinkage was remarkably low in cardiomyocytes. Cell shrinking was not prevented by pretreatment with 100 mmol/l of the broad-spectrum caspase inhibitor benzyloxycarbonyl-Val-Ala-Asp[Ome]-fluoromethylketone (z-VAD.fmk) (data not shown). Furthermore, after treatment with 1 mmol/l STS for 24 h, some myocardial cells kept on beating although at lower rates than control cells (60710 versus 22075 beats/min respectively, Po0.001, Student's t-test). In addition, cardiomyocytes treated for 24 h with 1 mmol/l STS recovered the sarcomer ultrastructure and its beating activity after withdrawal of the drug ( Figure 2 ). These results indicate that postnatal differentiated cardiomyocytes were resistant to STS-induced cytotoxicity.
Cardiomyocytes do not attain chromatin fragmentation after STS treatment
To explore whether STS induced apoptosis in cardiovascular cells, we first tested DNA damage as a marker of apoptotic cell death. In situ staining of the chromatin with bis-benzimide dye demonstrated that, in contrast to endothelial cells, cardiomyocyte nuclei did not fragment after treatment with 1 mmol/l STS for 24 h (Figure 3a ). To assess DNA cleavage, we performed agarose-gel electrophoresis of whole-DNA extracts from control cells and cells treated with 1 mmol/l for 24 h. Low molecular weight DNA fragmentation (laddering) was detected in STS-treated endothelium, but not in cardiomyocyte cultures (Figure 3b ). Furthermore, in cardiac cultures, nuclear fragmentation did not occur in cardiomyocytes but only in contaminant nonmyocardial cells, as demonstrated by immunocytochemical detection of cardiomyocyte-specific aactinin and nuclear staining in control and STS-treated cultures ( Figure 3c ). These results indicated the ability of cardiomyocytes to arrest the caspase-dependent apoptotic program before entering the execution phase.
STS triggers cytosolic translocation of cytochrome c in cardiomyocytes but fails to activate downstream apoptotic events STS-induced apoptotic cell death is mainly driven by the mitochondrial pathway. 15 Cytochrome c-defective cells are known to become resistant to STS-induced cell death, but Cardiomyocytes recover morphology and function after withdrawal of STS. Beating activity was measured in primary cultures of cardiomyocytes before STS addition to the culture medium at 1 mmol/l, during STS exposure (top bar¼24 h), and 24 and 48 h after withdrawal of the drug. Beating activity in every plate was calculated as the mean of beats per minute in five representative regions of the same plate and data in the graphic are expressed as mean 7 S.E.M. of three independent experiments. Fluorescence photomicrographs are representative images of myocardial cells stained for cardiac-specific a-actinin (red) and DNA (blue) at the points denoted in the time course with the same cap remain sensitive to death receptor stimulation. 17 It is also known that caspase-8-deficient cells are resistant to death receptor-induced apoptosis, but are still susceptible to STSinduced cell death. 18 STS was found to initiate morphological changes, characteristic of apoptotic death, both in cardiomyocytes and endothelial cells, but only the latter were able to follow the apoptotic program. To provide insight into the molecular pathways involved in the relative cardiomyocyte resistance to STS-triggered apoptosis, we first investigated to determine whether it was able to induce cytochrome c release into the cytosol. After 6 h of STS treatment, cytochrome c appeared in cytosolic extracts of endothelium and cardiomyocytes (Figure 4a ), increasing at 24 h. The time-dependent increase in cytosolic cytochrome c correlated with a decrease of the cytochrome c in the particulated fraction (Figure 4a , bottom panel). The possible role of antiapoptotic Bcl-2 family members in cardiomyocyte resistance to STS was ruled out, as these proteins mainly act by preventing cytochrome c release from mitochondria. 19 Caspase-3 activity has been reported in cardiomyocyte apoptosis. 20, 21 We analyzed caspase-3 activity by immunodetecting its active, processed form of approximately 20 kDa, by analyzing the cleavage of one of its specific substrates, fodrin, 22 and by measuring its enzymatic activity in extracts from control and STS-treated cells. STS treatment of endothelium induced a time-dependent cleavage of caspase-3 and fodrin, which is itself cleaved by caspase-3 rendering a fragment of 120 kDa. These effects were maximal after 24 h (Figure 4b ). The time course of caspase-3 and fodrin cleavage correlated with that of DNA laddering and endothelial cell death. However, this was not the case for cardiomyocytes. STS treatment of endothelium induced Cardiomyocyte resistance to the execution of the mitochondrial apoptotic program coincides with the deficiency in Apaf-1
Since activation of caspase-3 by the mitochondrial pathway implies assembly of the apoptosome, 23 incomplete formation of this complex could account for cytochrome c translocation without activation of caspase-3. As caspase-9 is present in cardiomyocytes, 24 we analyzed the presence of Apaf-1 as a major regulator of apoptosome activity. In contrast to endothelium, immunoreactive Apaf-1 was undetectable in Western blots of total cell lysates of rat primary cardiomyocyte cultures using an antibody raised against rat Apaf-1 ( Figure 5 ). In addition, Apaf-1 was present at high levels in primary cultures of rat heart fibroblasts and rat aorta-derived vascular smooth muscle cells (data not shown). These data suggested that lack of Apaf-1 expression could be a cardiomyocytespecific strategy to avoid completion of apoptosis by the mitochondrial pathway.
Restoration of Apaf-1 expression renders cardiomyocytes sensitive to STS-induced apoptosis
Taken together, the above-presented data pointed to Apaf-1 deficiency as the major cause of cardiomyocyte resistance to apoptosis driven by the mitochondrial pathway. In order to test this hypothesis, we performed transient transfection of cardiomyocyte primary cultures with a plasmid encoding for the Apaf-1 X L isoform. 25 These cultures were submitted to STS treatment and the occurrence of nuclear fragmentation as an indicator of cardiomyocyte apoptosis was investigated. Indeed, overexpression of Apaf-1 induced a three-fold increase in cardiomyocytes with fragmented nucleus ( Figure 6 ) compared to control cultures transfected with empty vector. Treatment with 1 mmol/l STS of cell cultures overexpressing Apaf-1 further increased cardiomyocyte nuclear fragmentation up to seven-fold. In addition, coexpression of the antiapoptotic protein Bcl-X L attenuated the effect of Apaf-1 ( Figure 6 ), therefore suggesting the participa- Protein loading Furthermore, although the involvement of the mitochondrial pathway has been suggested by other authors, 20 their data could not rule out the relevant role of the extrinsic pathway.
In our experimental model, nuclear fragmentation occurred in cardiomyocytes cultured in serum-free, glucose-free medium in the presence of 1 mmol/l 2-deoxy-D-glucose (Figure 7a 
Discussion
Loss of myocardial cell mass cannot be counterbalanced by cardiomyocyte renewal 26 and has been found to correlate with a bad outcome during the course of myocardial disease. Although myocardial cell loss has traditionally been attributed to necrosis, the contribution of apoptosis to cardiac disease is beginning to be unveiled. 4, 6, 27, 28 In the present work, we show that rat postnatal cardiomyocytes are resistant to STS-induced apoptosis, which is driven by the mitochondrial pathway through a mechanism involving proapoptotic Bcl2-family members Bax and Bak. 15 In spite of the incomplete apoptosis phenotype observed in cardiomyocytes, a significant part of the cells in our myocardial cultures died after STS treatment. Apoptosis of contaminant fibroblasts and endothelium, which express Apaf-1, could account, at least in part, for the observed cell death. We can also hypothesize that a small population of cardiomyocytes developed apoptosis after STS treatment by an Apaf-1-independent pathway. In fact, it has previously been reported that STS induces type-2 nuclear morphology and cell death in embryonic stem (ES) cells expressing Apaf-1 and that, after ablation of the Apaf-1 gene, STS does not induce further nuclear degradation but still causes cell death, although at a much lesser extent. Cardiomyocytes treated with STS underwent slight cellular shrinking and cytochrome c translocation to the cytosol, but showed neither caspase-3 activation nor nuclear fragmentation. This suggests the existence of antiapoptotic mechanisms acting downstream of cytochrome c release and upstream of the execution phase of apoptosis. These observations appear to be at variance with previously published works suggesting the relevant role of the mitochondrial pathway in cardiomyocyte apoptosis. Indeed, cytochrome c is released during hypoxia of neonatal 21 and adult cardiomyocytes. 30 Cytochrome c release and DNA fragmentation have been shown to occur in cultured neonatal cardiomyocytes under hypoxia during inhibition of glucose metabolism 21 and during serum and glucose deprivation. 20 However, the lack of data on the activation of the extrinsic pathway and a more in-depth analysis of the mitochondrial pathway do not allow to know for the determination of whether cytochrom c translocation is directly involved in the final apoptotic phenotype.
In this paper, we describe that nuclear condensation induced in cardiomyocytes by serum and glucose deprivation was suppressed by blocking the extrinsic apoptotic pathway with the specific caspase-8 inhibitor z.IETD.fmk. Although cytochrome c has been shown to be released in adult cardiomyocytes subjected to oxidative stress, 31 the activity of executioner caspases was not measured and apoptotic cells were defined as cells exposing phosphatidylserine in the outer outleaf of the cytosolic membrane, an early apoptotic event not directly related to the execution phase of the apoptotic process. 32 Finally, release of cytochrome c has been detected ex vivo in isolated whole rat hearts subjected to ischemia-reperfusion injury. 8 However, although processing of caspase-8 and caspase-9 was detected in tissue slices immunostained with specific antibodies against the cleaved forms, addition of z-LEHD.fmk, which was used as an inhibitor of caspase-9, did not clearly change the number of Tdtmediated dUTP nick end-labeling (TUNEL)-positive cardiomyocytes. 8 In fact, it has been reported that caspase-9 activity does not rely on structural processing but on the formation of the apoptosome. 33 In addition, recent evidence shows that caspase-9 processing could allow for binding to the inhibitor of apoptosis protein XIAP, suggesting that cleavage may instead have an inhibitory effect. 34 The relevance of cytochrome c release for cardiomyocyte apoptosis has always been proposed in complex experimental situations, under the assumption that downstream apoptotic machinery was present in myocardial cells. 30 On the contrary, our results are in agreement with a recent report showing that the release of cytochrome c was not correlated with the activation of caspase-3 in samples of failing human hearts. 7 In the present work, we have shown that Apaf-1 was absent in postnatal cardiomyocytes. This event could explain the lack of caspase-3 activation and nuclear fragmentation observed despite cytochrome c release. In our cultures, Apaf-1 deficiency was exclusive of cardiomyocytes, due to the fact that endothelium, cardiac fibroblasts and vascular smooth muscle cells expressed this protein. In fact, Apaf-1 gene repression has been described in tumor cell types resistant to drug-induced apoptosis. 35, 36 There is also evidence that supports that Apaf-1 expression could be lacking in skeletal myotubes 37 and adult cortical neurons. 38 However, although the latter work establishes a correlation between the expression of Apaf-1, the level of neuron maturation and the resistance to apoptosis, it does not have a functional approach. We report that transient expression of Apaf-1 in cardiomyocytes increased their susceptibility to undergo mitochondria-driven apoptosis. This effect was inhibited by antiapoptotic Bcl-2-related protein, Bcl-X L , further supporting the idea that lack of Apaf-1 expression prevents completion of cytochrome c-driven apoptosis in terminally differentiated myocardial cells.
We have demonstrated that cardiomyocytes are capable of arresting the apoptotic program when it occurs through the mitochondrial pathway, but they are still susceptible to apoptosis when induced by activation of death receptors. Our results are in agreement with works showing that cardiomyocyte apoptosis courses by the extrinsic pathway in experimental models of different types of heart disease. 16 Our work also agrees with the relevant role of the extrinsic pathway of apoptosis in the formation of the heart during embryogenesis. Indeed, morphologic alterations in the heart take place during embryogenesis in mice deficient for proteins involved in the extrinsic pathway (FADD, caspase-8, cFLIP), but not in null mice for proteins acting in the apoptotic mitochondrial pathway. 39 In conclusion, we report that in postnatal rat cardiomyocytes, the release of cytochrome c did not induce the activation of executioner caspases and nuclear fragmentation. We have also shown that the myocardial cells did not express Apaf-1, and that transient expression of this protein rendered cardiomyocytes prone to develop full canonic apoptosis upon stimulation of the mitochondrial pathway. In contrast, cardiomyocytes underwent apoptosis through the extrinsic pathway during serum deprivation and glucose metabolism inhibition. Our hypothesis is that lack of Apaf-1 is a mechanism developed by differentiated, postmitotic cardiomyocytes to block cytochrome c-driven apoptosis before entering the irreversible execution phase.
Material and Methods

Cell cultures and treatments
We obtained neonatal cardiomyocytes as described by Pelliux et al. 40 from the heart of 2-day-old Sprague-Dawley rat after digestion with type-2 collagenase (Worthington, Lakewood, NJ, USA). We used a two-round preplating in order to deplete cardiomyocyte culture of nonmyocardial cells. Cells were plated at a density of 10 3 cells/mm 2 in 1 g/l gelatin-coated FALCON polystyrene dishes (Becton Dickinson, Palo Alto, CA, USA) and NUNCLON four-well plates (NUNC, Denmark). The medium used was M199 : DMEM 1 : 3 (SIGMA-Aldrich Españ a, Alcobendas, Spain), pH 7.2 with 7.2 mmol/l glucose, 10% horse serum and 5% fetal calf serum (Gibco BRL/Izasa, Spain). Cardiomyocyte purity was checked by immunocytochemistry with a cardiac sarcomeric a-actinin monoclonal antibody (clone EA-53, SIGMA, St. Louis, MO, USA), and was found to be higher than 90% after 24 h in vitro. Deprivation was initiated after 24 h of plating, by culturing cells in DMEM minimal medium without serum and glucose (SIGMA), in the Apaf-1 deficiency blocks cardiomyocyte apoptosis D Sanchis et al presence of 1 mmol/l 2-deoxy-D-glucose (SIGMA). We added caspase-3 inhibitor z-DEVD.fmk and caspase-8 inhibitor z-IETD.fmk (Enzyme System Products, Livermore, CA, USA) at 100 mmol/l when indicated.
Cow pulmonary artery endothelial (CPAE) cell line was purchased from the European Cell Collection (ECACC, UK). We cultured CPAE cells in EMEM-1% nonessential aminoacids (SIGMA) and 20% FBS. STS (SIGMA) was added to the culture medium at the concentrations and times described in the figures.
Quantification of cell death
Detection of cell death was performed by the trypan blueexclusion assay after drug treatment for the times and concentrations described in the figures. Data are expressed as percentage of cell death in treated dishes versus equally loaded control dishes at time zero. Cell death for each experimental condition was measured in duplicate in three independent experiments.
DNA integrity assessment
Chromatin morphology was checked out by fluorescence microscopy after DNA staining with 0.5 mg/l. bis-Benzimide dye (Hoechst 33258) in cells previously fixed with 4% paraformaldehyde (PFA) (SIGMA) in Phosphatebuffered saline(PBS). DNA fragmentation was assessed by conventional agarose-gel electrophoresis as previously reported. 41 
DEVD-directed caspase activity
Caspase-3-like activity was measured as previously described. 42 Cells were treated 24 h after plating with 1 mmol/l STS for 24 hours, in the presence or absence of 100 mmol/l z-DEVD-fmk. Cells were lysed and protein concentration in the lysates was measured by the Bradford assay (BioRad, Alcobendas, Spain). Equal loads of protein were mixed with the fluorogenic substrate Ac-DEVD-afc at 50 mM (Enzyme Systems Products) in 96-well plates that were incubated at 371C and fluorescence was read at intervals of 1 h during the next 6 h in a Bio-tek FL 600 fluorimeter (Izasa, Madrid, Spain), with excitation filter set at 360 nm and emission filter at 530 nm. Data obtained for different experimental conditions were compared within the linear phase of absorbance increase.
Preparation of cytosolic extracts
Cytosolic fractions were obtained at the end of the treatments, in order to detect cytochrome c release from the mitochondria, by mixing pelleted cells in a buffer without detergent containing 220 mmol/l manitol (SIGMA). Cells were incubated on ice for 15 min and subjected to a serial centrifugation protocol 43 with some modifications. 41 Cytochrome c was measured in the cytosolic extract (supernatant) and the particulate fraction (pellet).
Protein extraction, Western blotting and immunocytochemistry
Cells were detached from the culture dishes, pelleted and washed twice with ice-cold PBS. After lysis in RIPA buffer, cells were centrifuged and the supernatant was used as whole-protein cell lysate. Protein concentration was then measured in total and cytosolic extracts by the Lowry assay. SDS-PAGE electrophoresis was performed and protein was electrotransferred to Immobilon-P filters (Millipore, Bedford, MA, USA) and reacted with the adequate primary antibodies. Immunoblots were exposed to an appropriate secondary peroxidase-conjugated antibody and developed with the SuperSignal Substrate (Pierce/Cultek, Madrid, Spain). Fluorescence immunocytochemistry of a-actinin and processed caspase-3 was performed in 4% PFA-fixed cultures permeabilized with 0.1% Triton-X (SIGMA) in PBS with 5% horse serum (SIGMA), mounted with Vectashield (Vector Laboratories, Burlingame, CA, USA) and visualized with an Olympus IX70 vertical epifluorescence phase-contrast microscope. Primary antibodies used were anti-human cytochrome c (BD-Pharmingen, Palo Alto, CA, USA); anti-human processed caspase-3 (Cell Signaling, Beverly, MA, USA); antihuman a-fodrin and anti-rat Apaf-1 (N-terminus) (Chemicon, Temecula, CA, USA).
Apaf-1 transfection
Full-length Apaf-1 from 293 T cells containing an 11-aminoacid NH 2 -terminal insert and an extra WD repeat cloned in pCDNA3 vector was generously supplied by Gabriel Nuñ ez (University of Michigan Medical School). We amplified this construct in E. coli Stbl2 strain (Invitrogen, Leek, The Netherlands) at 301C to avoid spontaneous mutations. Cardiomyocytes were transfected 3 h after plating by the LipofectAMINE s method (Invitrogen) with 0.5 mg of pcDNA3-Apaf-1X L , Bcl-X L 41 or empty vector, plus 0.5 mg of empty vector and 0.3 mg of pcDNA3-enhanced green fluorescent protein (EGFP) per 10 5 cells. Cotransfection of Apaf-1 and Bcl-X L was achieved by using a mixture of 0.5 mg of both the plasmids plus 0.3 mg of pcDNA3-EGFP. Transfected cultures were treated 24 h later with STS at a final concentration of 1 mmol/l for 24 h. Nuclear morphology was checked in parallel in STS-treated and untreated cultures 48 h after transfection. Cardiac-fragmented nuclei were counted after bis-benzimide staining in a-actinin-positive cells expressing EGFP. Data shown are the mean of three independent experiments made in duplicate.
